CLBR001/ABBV-461 / Scripps Research Institute, AbbVie - LARVOL DELTA

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=10 | Terminated | Sponsor: Calibr, a division of Scripps Research | N=20 ➔ 10 | Active, not recruiting ➔ Terminated; Business Decision

Enrollment change • Trial termination • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Calibr, a division of Scripps Research | Trial completion date: Nov 2028 ➔ Jun 2026 | Trial primary completion date: Nov 2028 ➔ Jun 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Calibr, a division of Scripps Research | Active, not recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Calibr, a division of Scripps Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Calibr-Skaggs doses first patient with switchable CAR-T cell therapy in a phase 1 trial for metastatic breast cancer (Eurekalert) - "The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors...The clinical trial testing CLBR001 + ABBV-461 is now underway in the US."

Trial status • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Triple Negative Breast Cancer

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Calibr, a division of Scripps Research | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Calibr, a division of Scripps Research

New P1 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer